Arrhythmogenesis in Timothy Syndrome is associated with defects in Ca2+-dependent inactivation
Timothy Syndrome (TS) is a multisystem disorder, prominently featuring cardiac action potential prolongation with paroxysms of life-threatening arrhythmias. The underlying defect is a single de novo missense mutation in Ca V 1.2 channels, either G406R or G402S. Notably, these mutations are often vie...
Gespeichert in:
Veröffentlicht in: | Nature communications 2016-01, Vol.7 (1), p.10370-12, Article 10370 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Timothy Syndrome (TS) is a multisystem disorder, prominently featuring cardiac action potential prolongation with paroxysms of life-threatening arrhythmias. The underlying defect is a single
de novo
missense mutation in Ca
V
1.2 channels, either G406R or G402S. Notably, these mutations are often viewed as equivalent, as they produce comparable defects in voltage-dependent inactivation and cause similar manifestations in patients. Yet, their effects on calcium-dependent inactivation (CDI) have remained uncertain. Here, we find a significant defect in CDI in TS channels, and uncover a remarkable divergence in the underlying mechanism for G406R versus G402S variants. Moreover, expression of these TS channels in cultured adult guinea pig myocytes, combined with a quantitative ventricular myocyte model, reveals a threshold behaviour in the induction of arrhythmias due to TS channel expression, suggesting an important therapeutic principle: a small shift in the complement of mutant versus wild-type channels may confer significant clinical improvement.
Timothy Syndrome (TS) is a multisystem disorder caused by two mutations leading to dysfunction of the Ca
V
1.2 channel. Here, Dick
et al
. uncover a major and mechanistically divergent effect of both mutations on Ca
2+
/calmodulin-dependent inactivation of Ca
V
1.2 channels, suggesting genetic variant-tailored therapy for TS treatment. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/ncomms10370 |